LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MRSA Identified Using Nasal Swabs

By LabMedica International staff writers
Posted on 13 Sep 2012
Print article
Methicillin-resistant Staphylococcus aureus (MRSA) infections have been detected by nasal swabbing using agar culture methods.

The proportion of patients with MRSA that were correctly identified by nasal swabs has been compared with multiple body site testing using agar and nutrient broth culture.

A cross-sectional study has been carried out by the Health Protection Scotland (Glasgow, UK) on adult patients admitted to 36 general specialty wards of two large hospitals in Scotland (UK). Patients were screened for MRSA via multiple body site swabs such as nasal, throat, axillary, perineal, wound, and invasive device sites. These were cultured individually on Brilliance MRSA chromogenic agar (Oxoid; Basingstoke, UK) and pooled in nutrient broth. Suspect colonies were confirmed by a coagulase test using the Prolex Staph Xtra Latex kit (Pro-Lab Diagnostics; Bromborough, UK). Combined results from all sites and cultures provided a gold-standard estimate of true MRSA prevalence.

The scientist found that nasal screening performed better than throat, axillary, or perineal screening, but only identified 66% of true MRSA carriers against the gold standard at an overall prevalence of 2.9%. Axillary screening performed least well. Combining nasal and perineal swabs gave the best two-site combination with 82%. When combined with realistic screening compliance rates of 80%-90%, nasal swabbing alone probably detects just over half of true colonization in practice. Swabbing of clinically relevant sites such as wounds and indwelling devices, is important for a small but high-prevalence group.

The investigators concluded that nasal swabbing is the standard method in many locations for MRSA screening. Its diagnostic efficiency in practice appears to be limited, however, and the resource implications of multiple body site screening have to be balanced against a potential clinical benefit whose magnitude and nature remains unclear. The study was published in the August 2012 issue of the journal Infection Control and Hospital Epidemiology.

Related Links:

Health Protection Scotland
Oxoid
Pro-Lab Diagnostics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.